ConductScience.org, home

Paper34406366

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.

Eichenfield LF and 14 others. JAMA Dermatol, 2021. Cited by 139 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. Papers, record 34406366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34406366

Download JSON
Disease
atopic eczema238 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
PubMed
Journal
JAMA Dermatol
PubMed
Year
2021
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
139
iCite
Relative citation ratio, by iCite
10.5
iCite
Revised in PubMed
2022-03-25
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Eichenfield LFLawrence F
2Flohr CCarsten
3Sidbury RRobert
4Siegfried EElaine
5Szalai ZZsuzsanna
6Galus RRyszard
7Yao ZZhirong
8Takahashi HHidetoshi
9Barbarot SSébastien
10Feeney CClaire
11Zhang FFan
12DiBonaventura MMarco
13Rojo RRicardo
14Valdez HHernan
15Chan GGary

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Dermatitis, AtopicMajor topic
EczemaMajor topic
Adolescent
Child
Double-Blind Method
Female
Humans
Male
Pyrimidines
Severity of Illness Index
Sulfonamides
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03796676JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in34668957Errors in Table 1, Figure 3, and Results.https://conductscience.org/library/papers/34668957

Source PubMed

Download CSV of comments and corrections

Cited by78

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 139 citations.

PMIDTitleJournalYearIn PapersSource
42844558Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42844558PubMed
42789457Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatr Allergy Immunol2026https://conductscience.org/library/papers/42789457PubMed
42667571Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims.Adv Ther2026https://conductscience.org/library/papers/42667571PubMed
42630413A systemic epithelial-immune-neural framework for pediatric atopic dermatitis-allergic rhinitis comorbidity.Front Immunol2026https://conductscience.org/library/papers/42630413PubMed
42577450Efficacy and safety of the JAK1 inhibitor abrocitinib for moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/42577450PubMed
42415197The JAK-STAT pathway in allergic diseases: from pathogenesis to targeted therapy.Biomark Res2026https://conductscience.org/library/papers/42415197PubMed
42356139Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study.Medicina (Kaunas)2026https://conductscience.org/library/papers/42356139PubMed
42328000
Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.
Allergol Select2026https://conductscience.org/library/papers/42328000PubMed
42220541Real-world effectiveness and safety of 200 mg abrocitinib initiation in Chinese adults with moderate-to-severe atopic dermatitis: a retrospective study.Front Immunol2026https://conductscience.org/library/papers/42220541PubMed
42187316Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.J Eur Acad Dermatol Venereol2026https://conductscience.org/library/papers/42187316PubMed
42162528Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42162528PubMed
42148141Comparative efficacy of pediatric atopic dermatitis treatments: a network meta-analysis highlighting dupilumab and pimecrolimus for SCORAD and EASI improvement.Front Immunol2026https://conductscience.org/library/papers/42148141PubMed
42047411Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.J Eur Acad Dermatol Venereol2026https://conductscience.org/library/papers/42047411PubMed
42018850Use of abrocitinib in severe atopic dermatitis.Rev Assoc Med Bras (1992)2026https://conductscience.org/library/papers/42018850PubMed
42008061Treatment Patterns and Perceptions of Treatment Options in Japanese Pediatric and Adolescent Patients with Atopic Dermatitis.Adv Ther2026https://conductscience.org/library/papers/42008061PubMed
41897097Real-World Treatment Patterns and Determinants of Therapy in Pediatric Atopic Dermatitis: A 10-Year Experience from a Tertiary Referral Center in Thailand.Children (Basel)2026https://conductscience.org/library/papers/41897097PubMed
41670770Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/41670770PubMed
41413320Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/41413320PubMed
41405747Pathophysiologic Mechanisms and Targeted Treatments Associated with the Nervous System in Cutaneous Allergic Diseases.Clin Rev Allergy Immunol2025https://conductscience.org/library/papers/41405747PubMed
41403263Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial.Acta Derm Venereol2025https://conductscience.org/library/papers/41403263PubMed

See all 78 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
LOC102723407102723407PubTator's text mininghttps://conductscience.org/library/genes/102723407NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ABROCITINIBCHEMBL3655081Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3655081

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34406366

GET https://conductscience.org/api/papers/v1/34406366/cited_by?page=2